
    
      In the study, intravenous bendamustine will be administered at a dose of 90 mg/m2 on day 1
      and 2 and brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of
      each 21 days-based cycle, for 6 cycles. All patients achieving a CR can be considered
      eligible to peripheral blood stem cell mobilization (to be performed with granulocytecolony
      stimulating factor alone) and may proceed to an ASCT at any time after cycle 4.
    
  